Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results
Lopez et al.,
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results,
Int. J. Antimicrob. Agents, doi:/j.ijantimicag.2020.106136
Small retrospective study of 29 ICU patients comparing those with HCQ plasma concentration within target to those with a concentration below the target value, with no significant differences found. Mortality in the on-target group was 0% versus 17% for the off-target group, mortality relative risk 0.14, p = 0.16.
Lopez et al., 8 Aug 2020, peer-reviewed, 8 authors.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
International Journal of Antimicrobial Agents 56 (2020) 106136
Contents lists available at ScienceDirect
International Journal of Antimicrobial Agents
journal homepage: www.elsevier.com/locate/ijantimicag
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit
Patients: Preliminary Results
Alexandre Lopez a,∗, Gary Duclos a, Bruno Pastene a, Karine Bezulier a, Romain Guilhaumou b,
Caroline Solas c, Laurent Zieleskiewicz a,d, Marc Leone a
a
Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015,
France
Service de Pharmacologie Clinique et Pharmacovigilance, APHM, Institut de neurosciences des systèmes, Inserm UMR 1106, Université d’Aix-Marseille,
France.
c
Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital
La Timone, 13005 Marseille, France
d
Center for Cardiovascular and Nutrition Research (C2VN) Aix Marseille Université, INSERM, INRA, Marseille, 13005, France.
b
a r t i c l e
Keywords:
Hydroxychloroquine
Intensive care unit
Covid-19 pneumonia
i n f o
a b s t r a c t
During the Covid-19 pandemic, many intensive care unit (ICU) patients received hydroxychloroquine. The
primary objective of this study was to assess the effects of hydroxychloroquine according to its plasma
concentration in ICU patients. A single-center retrospective study was performed from March to April
2020 in an ICU of a university hospital. All patients admitted to the ICU with confirmed Covid-19 pneumonia and treated with hydroxychloroquine were included. The study compared 17 patients in whom
the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients
in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15
days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (P = 0.77). There was no significant difference between the two groups for duration of mechanical
ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. These findings indicate that
hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. Larger multicenter studies are needed to confirm these results.
© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit